Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
The funding round is led by Kalaari Capital. Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round
Lidocaine and Prilocaine Cream USP, 2.5%/2.5% has an estimated market size of US $ 29 million for twelve months ending Dec. 2021 according to IQVIA
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Crosscope Dx is a workflow integrated vendor-agnostic digital pathology platform that offers end-to-end digital pathology solutions with advanced workflow features
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Subscribe To Our Newsletter & Stay Updated
